Anthony Lembo

Anthony Lembo


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2003 in New England Journal of Medicine
Verified
Journal Article
Closed access
ALAnthony Lembo
Anthony Lembo
MCMichael Camilleri
Michael Camilleri
Chronic constipation is a common condition that can be debilitating and difficult to treat. This review explains the physiologic processes involved in colonic transit and defecation. The evaluation of patients is summarized along with current strategies for clinical management.

12 August 2019 in Neurogastroenterology & Motility
Verified
Journal Article
Open access
PDF file
ECEmma V. Carrington
Emma V. Carrington
HHHenriette Heinrich
Henriette Heinrich
CKCharles H. Knowles
Charles H. Knowles
Mark FoxMark Fox
Mark Fox
SRSatish Rao
Satish Rao
AGAll members of the International Anorectal Physiology Working Group
All members of the International Anorectal Physiology Working Group
Background: This manuscript summarizes consensus reached by the International Anorectal Physiology Working Group (IAPWG) for the performance, terminology used, and interpretation of anorectal function testing including anorectal manometry (focused on high‐resolution manometry), the rectal sensory test, and the balloon expulsion test. Based on these measurements, a classification system for disorders of anorectal function is proposed.Methods: Twenty‐nine working group members (clinicians/academics in the field of gastroenterology, coloproctology, and gastrointestinal physiology) were invited to six face‐to‐face and three remote meetings to derive consensus between 2014 and 2018.Key recommendations: The IAPWG protocol for the performance of anorectal function testing recommends a standardized sequence of maneuvers to test rectoanal reflexes, anal tone and contractility, rectoanal coordination, and rectal sensation. Major findings not seen in healthy controls defined by the classification are as follows: rectoanal areflexia, anal hypotension and hypocontractility, rectal hyposensitivity, and hypersensitivity. Minor and inconclusive findings that can be present in health and require additional information prior to diagnosis include anal hypertension and dyssynergia.Conclusions and Inferences: This framework introduces the IAPWG protocol and the London classification for disorders of anorectal function based on objective physiological measurement. The use of a common language to describe results of diagnostic tests, standard operating procedures, and a consensus classification system is designed to bring much‐needed standardization to these techniques.

21 January 2016 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ALAnthony Lembo
Anthony Lembo
BLBrian E. Lacy
Brian E. Lacy
MZMarc J. Zuckerman
Marc J. Zuckerman
RSRon Schey
Ron Schey
LDLeonard S. Dove
Leonard S. Dove
PCPaul S. Covington
Paul S. Covington
Effective and safe treatments are needed for patients who have irritable bowel syndrome (IBS) with diarrhea. We conducted two phase 3 trials to assess the efficacy and safety of eluxadoline, a new oral agent with mixed opioid effects (μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist), in patients with IBS with diarrhea.

1 December 2016 in Gastroenterology
Verified
Journal Article
Open access
ALAnthony Lembo
Anthony Lembo
MPMark Pimentel
Mark Pimentel
SRSatish S. Rao
Satish S. Rao
PSPhilip Schoenfeld
Philip Schoenfeld
BCBrooks Cash
Brooks Cash
WFWilliam P. Forbes
William P. Forbes
Few treatments have demonstrated efficacy and safety for diarrhea-predominant irritable bowel syndrome (IBS-D). A phase 3, randomized, double-blind, placebo-controlled trial was performed to evaluate the safety and efficacy of repeat treatment with the nonsystemic antibiotic rifaximin. The trial included adults with IBS-D, mean abdominal pain and bloating scores of 3 or more, and loose stool, located at 270 centers in the United States and Europe from February 2012 through June 2014. Those responding to a 2-week course of open-label rifaximin 550 mg 3 times daily, who then relapsed during an observation phase (up to 18 weeks), were randomly assigned to groups given repeat treatments of rifaximin 550 mg or placebo 3 times daily for 2 weeks. The primary end point was percentage of responders after first repeat treatment, defined as a decrease in abdominal pain of ≥30% from baseline and a decrease in frequency of loose stools of ≥50% from baseline, for 2 or more weeks during a 4-week post-treatment period. Of 1074 patients (44.1%) who responded to open-label rifaximin, 382 (35.6%) did not relapse and 692 (64.4%) did; of these, 636 were randomly assigned to receive repeat treatment with rifaximin (n = 328) or placebo (n = 308). The percentage of responders was significantly greater with rifaximin than placebo (38.1% vs 31.5%; P = .03). The percentage of responders for abdominal pain (50.6% vs 42.2%; P = .018) was significantly greater with rifaximin than placebo, but not stool consistency (51.8% vs 50.0%; P = .42). Significant improvements were also noted for prevention of recurrence, durable response, and bowel movement urgency. Adverse event rates were low and similar between groups. In a phase 3 study of patients with relapsing symptoms of IBS-D, repeat rifaximin treatment was efficacious and well tolerated. ClinicalTrials.gov ID: NCT01543178.

1 March 2005 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
SPS. M. Patel
S. M. Patel
WSW. B. Stason
W. B. Stason
ALA. Legedza
A. Legedza
SOS. M. Ock
S. M. Ock
TKT. J. Kaptchuk
T. J. Kaptchuk
ALAnthony Lembo
Anthony Lembo

1 July 2016 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
ALAnthony Lembo
Anthony Lembo
MCMichael Camilleri
Michael Camilleri
RMRichard McCallum
Richard McCallum
RSRamon Sastre
Ramon Sastre
CBCristian Breton
Cristian Breton
RGRM-131-004 Trial Group
RM-131-004 Trial Group